Adalimumab for Nail Psoriasis: Efficacy and Safety From the First 26 weeks of a Phase 3, Randomized, Placebo-Controlled Trial
Journal of the American Academy of Dermatology - United States
doi 10.1016/j.jaad.2017.08.029
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2018
Authors
Publisher
Elsevier BV